安旭生物(688075) - 2024 Q4 - 年度业绩

Financial Performance - Total revenue for 2024 reached RMB 55,515.25 million, an increase of 10.29% compared to the previous year[4] - Net profit attributable to shareholders of the parent company was RMB 20,108.90 million, up 42.06% year-on-year[4] - Basic earnings per share increased to RMB 1.58, reflecting a growth of 42.34% from the previous year[4] - The net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, decreased by 32.38% to RMB 3,539.52 million[4] - The increase in profit was primarily driven by revenue growth and investment income[7] Assets and Equity - Total assets at the end of the reporting period were RMB 576,507.48 million, a decrease of 0.42% from the beginning of the year[4] - Shareholders' equity attributable to the parent company rose to RMB 521,060.41 million, an increase of 1.98% year-on-year[4] Business Strategy - The company focused on the POCT in vitro diagnostic field, enhancing customer demand and expanding both domestic and international markets[6] - The company implemented various measures to improve management and production efficiency, contributing to performance enhancement[6] Financial Reporting - The financial data presented is preliminary and subject to final audit in the annual report[8]